AZ at it again

AUTH/2793/9/15 - Clinical pharmacist v AstraZenecaCase number:AUTH/2793/9/15Case ref:Clinical pharmacist v AstraZenecaDescription:Identifying patients suitable for Forxiga treatment and failing to provide an accurate response to the PanelNo breach:No breaches Clauses 2 and 7.2Breach:Breaches Clauses 3.2, 7.2 and 9.1. Corrective statement and public reprimand.Appeal:No appealReview:Published in the May 2016 ReviewReceived:10/09/2015Completed:17/03/20162793Case Summary:​​​​A clinical pharmacist complained about an AstraZeneca leavepiece about how to create a clinical system search to identify patients suitable for treatment with Forxiga (dapagliflozin). Forxiga was indicated in adults with type 2 diabetes to improve glycaemic control as monotherapy when diet and exercise alone did not provide adequate glycaemic control in patients for whom use of metformin was considered inappropriate due to intolerance. It was also indicated in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, did not provide adequate glycaemic control.The leavepiece was entitled ‘9 step guide to identify your uncontrolled and overweight patients with type 2 diabetes (T2D) who may be suitable for treatment with dapagliflozin EMIS Web Instructions’. The front page included ‘FORXIGA is not indicated for weight loss and is not recommended for use in patients with an [eGFR ]< 60 mL/min/1.73m2. FORXIGA is not licensed for...
Source: PharmaGossip - Category: Pharmaceuticals Authors: Source Type: blogs